Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
GOSS | US
0.02
1.90%
Healthcare
Biotechnology
30/06/2024
04/10/2024
1.07
1.02
1.09
1.00
Gossamer Bio Inc. a clinical-stage biopharmaceutical company focuses on discovering acquiring developing and commercializing therapeutics in the disease areas of immunology inflammation and oncology in the United States. The company is developing GB002 an inhaled small molecule platelet-derived growth factor receptor or PDGFR colonystimulating factor 1 receptor or CSF1R and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004 a gut-targeted oral small molecule for the treatment of inflammatory bowel disease; GB5121 an oral irreversible covalent small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208 an oral small molecule BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG Bio Inc. and changed its name to Gossamer Bio Inc. in 2017. Gossamer Bio Inc. was incorporated in 2015 and is headquartered in San Diego California.
View LessPositive Momentum
Strength based on increasing price with high volume
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
67.4%1 month
68.9%3 months
72.7%6 months
86.5%-
-
2.66
2.44
0.53
-0.39
0.64
-
-68.23M
242.06M
242.06M
-
54.35
-
-
-863.39
10.50
3.89
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.18
Range1M
0.28
Range3M
0.60
Rel. volume
1.43
Price X volume
1.47M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Progenitor Inc | PGEN | Biotechnology | 0.9 | 263.38M | -6.82% | n/a | 14.69% |
Mersana Therapeutics Inc | MRSN | Biotechnology | 2.12 | 260.07M | 3.92% | n/a | 383.37% |
ChromaDex Corporation | CDXC | Biotechnology | 3.38 | 256.65M | -2.59% | n/a | 10.17% |
Poseida Therapeutics Inc | PSTX | Biotechnology | 2.61 | 253.52M | -1.14% | n/a | 137.55% |
Fulcrum Therapeutics Inc | FULC | Biotechnology | 3.82 | 252.91M | -1.29% | n/a | 3.53% |
Amarin Corporation plc | AMRN | Biotechnology | 0.6058 | 249.09M | 0.30% | n/a | 1.47% |
2seventy bio Inc | TSVT | Biotechnology | 4.81 | 247.70M | 0.00% | n/a | 107.07% |
Nanobiotix S.A | NBTX | Biotechnology | 5.19 | 246.03M | 0.00% | n/a | -2742.14% |
Adaptimmune Therapeutics plc | ADAP | Biotechnology | 0.951 | 243.21M | 8.72% | n/a | 49.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.39 | 0.76 | Cheaper |
Ent. to Revenue | 0.64 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 2.66 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 72.67 | 74.67 | Par |
Debt to Equity | 2.44 | -1.82 | Expensive |
Debt to Assets | 0.53 | 0.26 | Expensive |
Market Cap | 242.06M | 3.73B | Emerging |